Global Cancer Antibody Drug Conjugates Market: 2020 - 2030 Global Cancer Antibody Drug Conjugates Market Opportunity > US$ 50 ...

Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech ...

Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer ...

Tanya Gupta, MD, discusses the use of ado-trastuzumab emtansine for the treatment of patients with HER2-positive breast cancer.

Older adults with metastatic cancer living in Mexico experience a high time toxicity burden, spending about 21% of their days ...

DelveInsight's Antibody-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...

Scientists have engineered CAR-T cells with on/off switches activated by existing drugs, enhancing safety in cancer therapy.

Changes in the gene activity of immune cells may help flag people who have multiple sclerosis or are likely to develop it, a ...

Under the revised agreement, both companies will co-develop four Radio-DARPin programs; each company will have the right to commercialize two ...

DelveInsight's 'Antibody-drug Conjugates in Oncology Competitive Landscape – 2024' report provides comprehensive global ...

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce the issuance of U.S. Patent No.

Tevogen is driven by a team of experienced industry leaders and scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized ...